Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2018

View Archived Issues

Ionis licenses IONIS-AZ5-2.5Rx to AstraZeneca

Wave Life Sciences forms global CNS collaboration with Takeda

MSD and Viralytics enter definitive acquisition agreement to advance immuno-oncology pipeline

AbbVie announces topline results from phase III trial of elagolix for uterine fibroids

Evofem Biosciences' Amphora granted FDA fast track designation for prevention of chlamydia

Researchers discover OAT-2068, a highly selective and orally bioavailable inhibitor of mCHIT1

BioArctic receives approval to include Estonian patients in SC-0806 trial in spinal cord injury

First patient dosed in Centrexion's phase III trial of CNTX-4975 for moderate to severe knee OA pain

Medshine Discovery divulges new compounds for cytomegalovirus infection

Suzhou Guokuang Pharmtech, Hangzhou Adlai Nortye Pharmaceutical Technology patent IDO/TDO inhibitors

Novel SSAO inhibitors discovered at Lilly

Phase II data presented for RM-1929 photoimmunotherapy in patients with rHNSCC

Shenzhen Targetrx Biotechnology describes new HCV NS3/NS4A inhibitors

Erleada available to order in U.S. through Biologics

Phase IIa study of GWP-42006 in adults with focal seizures did not meet its primary endpoint

STA Pharmaceutical and Regulus sign oligonucleotide synthesis collaboration agreement

Phase III study of Mesoblast's remestemcel-L in acute GvHD meets primary endpoint

NIAID initiates phase I study of MERS-CoV antibodies REGN-3048 and REGN-3051

Endoscopic and symptom improvement seen with apremilast in phase II ulcerative colitis trial

EMA committee communicates positive trend vote for rucaparib

Vertex announces phase III study of VX-659, tezacaftor and ivacaftor for cystic fibrosis

TopiVert presents phase I data for TOP-1288 in healthy volunteers

Mouse model reveals role of the OTUD7A gene in 15q13.3 microdeletion syndrome

Tenofovir exalidex granted U.S. orphan designation for pediatric HBV infection

Tell us about your experience with TRDN

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...